# Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

> **NCT03907540** · PHASE1 · COMPLETED · sponsor: **Kadmon Corporation, LLC** · enrollment: 5 (actual)

## Conditions studied

- Autoimmune Diseases
- Fibrosis

## Interventions

- **DRUG:** Belumosudil 200 mg tablet
- **DRUG:** [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose
- **DRUG:** [14C]-KD025 200 mg capsule

## Key facts

- **NCT ID:** NCT03907540
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-05
- **Primary completion:** 2019-05-20
- **Final completion:** 2019-05-20
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2022-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03907540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03907540, "Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03907540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*